TG Therapeutics is a commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, Co. has received approval from the U.S. Food and Drug Administration for BRIUMVI™ (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Co. also evaluates products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. We show 53 historical shares outstanding datapoints in our coverage of TGTX's shares outstanding history.
Understanding the changing numbers of TGTX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like TGTX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching TGTX by allowing them to research TGTX shares outstanding history
as well as any other stock in our coverage universe. |
Free TGTX Email Alerts:
Video: Shares Outstanding Importance
